Skip to main content

List of patents
CODE DESCRIPTION PRIORITY LICENSE
98002 IFNa5 Interferon alfa 5 use as antiviral for hepatitis C treatment Sol. ES9801003;
13/05/1998
DIGNA BIOTECH
98003 iTGFb1 Peptide inhibitors of TGF beta 1 Sol. ES9802465;
24/11/1998
DIGNA BIOTECH
01008 CT-1 Use of Cardiotrophine (CT-1) for the treatment of human liver diseases Sol. ES200102120;
21/09/2001
DIGNA BIOTECH
02007 iTGFb1 II Peptides Inhibitors of TGF-beta 1 (II) Sol. ES200302020; 22/08/2003 DIGNA BIOTECH
03001 EPCR New method for thrombosis risk evaluation by measuring EPCR auto-antibody in plasma Sol. ES200400269;
06/02/2004
DIGNA BIOTECH
03004 AdSFV Vec Hybrid virus (Adenovirus-alfa/ Semliky Forest) to administer and express therapeutics genes in tumour cells Sol. ES200401219;
20/05/2004
DIGNA BIOTECH
04005 AR Use of anfirreguline as acute liver protectant agent Sol. ES200401776;
20/07/2004
DIGNA BIOTECH
04011 ApoA1 HCC Oxidised Apo A1 as early markers of Hepatocellular carcinoma Sol. ES200402989;
16/12/2004
DIGNA BIOTECH
05003 MAPC Vascular/Lymphatic Endothelial Cells derived from mature adult stem cell Sol.US 60/652,015; 10/02/2005 Joint owner with University of Minnesota (USA)
04007 nsEPCR New soluble ePCR protein as trombotic marker and potential therapeutic agent Sol. ES200500623;
17/03/2005
DIGNA BIOTECH
04016 MTA Autoin 5'-metiltioadenosina (MTA) in the prevention and treatment of autoimmune diseases PCT/ES 2005/000139; 17/03/2005 DIGNA BIOTECH
05004 EWS-FLI1 Animal model of human Ewing sarcoma PCT/ES 2005/000234; 29/04/2005  
05008 IFNa.CT1 Use of cardiotrophine-1 (CT-1) and alfa interferon (IFNa) for combined treatment in viral diseases Sol. ES200501468;
16/06/2005
DIGNA BIOTECH
05012 URIFIB Fibrosis markers in urine Sol. ES200501611; 01/07/2005 DIGNA BIOTECH
04018 EDA Vac Use of EDA as immune-modulator agent Sol. ES200501412; 13/06/2005 DIGNA BIOTECH
05013 HCC.Prof A selection of hepatocellular carcinoma markers Sol. ES200502369;
29/09/2005
DIGNA BIOTECH
05009 HCV poliIC.aCD40 Immune-stimulatory combination for hepatitis C prevention Sol. ES200601563;
09/06/2006
DIGNA BIOTECH
05030 iTGFb1 INMUN Use of peptides inhibitor of TGF-beta1 as a immune response modulator PCT/ES 2005/000569; 24/10/2005 DIGNA BIOTECH
05029 DTh.panDR New synthetic peptides as T helper (DTh) determinant for universal DR Sol. ES200503169;
23/12/2005
 
06010 BrC.Predictor 11q deletion as a molecular genetic marker in breast cancer Sol. US11/382,99;
12/05/2006
Joint owner with University of California (USA)
06016 iIL10 IL-10 inhibitors peptides (iIL-10) Sol. ES200700806; 27/03/2007 DIGNA BIOTECH
06022 Prot.Prod Viral vector as producer for stable cell line generation Sol. ES200700882;
03/04/2007
3P BIOPHARMACEUTICALS
06024 iFoxp3 Escurfine inhibitors peptides (i Fox p3) Sol. ES200703052; 19/11/2007; PCT / ES2008000716 DIGNA BIOTECH
06031 MMP10.coag Metalloproteinase 10 as adjuvant for trombolitic treatment (MMP10) Sol. ES200700501;
26/02/2007
DIGNA BIOTECH
07014 aMMP10.Blood Metalloproteinase 10 Inhibitors as anti-fibrinolitic treatment (iMMP10) Sol. ES200701786;
26/06/2007
DIGNA BIOTECH
07016 TGFb1-MMPs Metalloproteinase in combination with iTGF beta for metastasis treatment (MMPs+iTGFbeta-1) Sol. ES200702309;
20/08/2007
DIGNA BIOTECH
05033 PPARa CPH Inhibitors of PPAR alfa truncated for heart failure prevention in hypertension (iPPAR truncated) Sol. ES200702625;
05/10/2007
DIGNA BIOTECH
07005 IFN.CD137 Association of alfa interferon to 4-1BB agonist antibodies for antitumoral treatment (alfa INF+4-1BB agonist) Sol. ES200702961; 07/11/2007; Sol. PCT/ES2008000693 DIGNA BIOTECH
07027 IL12.iTGFb1 iTGF beta 1 as adjuvant for the antitumoral effect of IL12 induced expression (IL12+iTGF beta1) Sol. ES200800417;
15/02/2008
DIGNA BIOTECH
06002 PBGD
Porfiria TG
Porphobilinogen deaminase gene therapy Sol. US 61/100881;
29/09/2008
AMT
07024 U1.RNAi Synergy of silencing post-transcriptional genes combining mRNAi and snRNP (mRNAi + sn RNP U1) Sol. ES200800222;
29/01/2008
DIGNA BIOTECH
06027 PCP.PCPE Methods for the treatment of cardiac disease associated to myocardial fibrosis PCT/EP 2008/051347; 04/02/2008 DIGNA BIOTECH
07031 4PBA.Alz Novel uses for 4-phenylbutyrate (4PBA) and its pharmaceutically acceptable salts Sol. ES200800736;
13/3/2008
DIGNA BIOTECH
07037 MTA.Glat Synergystic combinations of 5'-methylthioadenosine Sol. ES200800806;
19/03/2008
DIGNA BIOTECH
08002 AdH.Cre Self-inactivating helper adnoviruses for the production of high-capacity recombinant adenoviruses Sol. ES200801434;
16/05/2008
 
07038 Packsis System for packaging of high-capacity adenovirus Sol. ES200801682;
04/06/2008
DIGNA BIOTECH
08005 ApoA1.vec Conjugates for the administration of biologically active compounds Sol. ES200801796;
13/06/2008
DIGNA BIOTECH
07017 aWnt.HCC Anti-angiogenic agents Sol. ES200802023; 02/07/2008 DIGNA BIOTECH
08014 RHOB.NSCLC Novel biomarker as a therapeutic target in lung cancer Sol. ES200802503;
28/08/2008
DIGNA BIOTECH
08007 PSM.vac Use of phenol soluble modulins for the development of vaccines Sol. ES200803441;
03/12/2008
DIGNA BIOTECH
07022 Urifib II Biomarkers for the diagnosis of fibrosis Sol. ES200900056; 09/01/2009  
07009 CT-1 Obe Use of cardiotrophin 1 for the treatment of metabolic diseases Sol. ES200900396;
12/02/2009
 
08018 IFNa.OSM.Cancer Oncostatin M as an enhancer of the immunostimulatory activity of human epithelial cells Sol. ES200802835;
07/10/2008
DIGNA BIOTECH
08004 iA2a Ad.Rc Compounds for the treatment of auricular fibrillation Sol. ES200502545;
14/10/2005
DIGNA BIOTECH

© Proyecto de Biomedicina CIMA S.L.

Avda. Pio XII, 22. Oficina 1 · 31008 Pamplona · Navarra · Spain · T +34 948 287 561 · F +34 948 180 500 · info@proyectobiocima.com